Notably, our study has two significant limitations: it does not investigate the potential impact of SIGMAR1 on the sensitivity or resistance to other commonly used oral cancer treatments, and the small number of analyzed samples in our validation study may affect the generalizability of our findings. This evidence concerns the gene SIGMAR1 and lip and oral cavity carcinoma.